Artwork
iconShare
 
Manage episode 495665864 series 3645668
Content provided by Schwab Network. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Schwab Network or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://staging.podcastplayer.com/legal.

Sarepta Therapeutics (SRPT) shares are getting crushed after a series of analyst downgrades on the heels of an FDA request to stop its Elevidys treatment. Rachel Dashiell diagnoses the biotech company's technical patterns taking shape on the chart. For the short-term chart, she sees resistance around $17 amid a strong downtrend. On the longer 15-year timeframe, Rachel says the 200-day moving average has acted as long term support for about 7 years around the $120 point.

======== Schwab Network ========

Empowering every investor and trader, every market day.

Subscribe to the Market Minute newsletter - https://schwabnetwork.com/subscribe

Download the iOS app - https://apps.apple.com/us/app/schwab-network/id1460719185

Download the Amazon Fire Tv App - https://www.amazon.com/TD-Ameritrade-Network/dp/B07KRD76C7

Watch on Sling - https://watch.sling.com/1/asset/191928615bd8d47686f94682aefaa007/watch

Watch on Vizio - https://www.vizio.com/en/watchfreeplus-explore

Watch on DistroTV - https://www.distro.tv/live/schwab-network/

Follow us on X – / schwabnetwork

Follow us on Facebook – / schwabnetwork

Follow us on LinkedIn - / schwab-network

About Schwab Network - https://schwabnetwork.com/about

  continue reading

6136 episodes